Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ORIC 
Oric Pharmaceuticals Inc (ORIC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ORIC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $18
1 Year Target Price $18
| 10 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.49% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 974.14M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 12 | Beta 1.69 | 52 Weeks Range 3.90 - 14.67 | Updated Date 08/29/2025 |
52 Weeks Range 3.90 - 14.67 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.89 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.44 | Actual -0.47 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.69% | Return on Equity (TTM) -43.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 717241846 | Price to Sales(TTM) - |
Enterprise Value 717241846 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 97123000 | Shares Floating 63296993 |
Shares Outstanding 97123000 | Shares Floating 63296993 | ||
Percent Insiders 6.94 | Percent Institutions 98.58 |
Upturn AI SWOT
Oric Pharmaceuticals Inc
Company Overview
History and Background
Oric Pharmaceuticals, Inc. (ORIC) is a biopharmaceutical company focused on developing therapies that overcome resistance mechanisms in cancer. Founded in 2014, the company went public in 2020. Its focus is on developing precision medicines for cancers, particularly those driven by steroid hormone receptors.
Core Business Areas
- Oncology Drug Development: Oric Pharmaceuticals focuses on research, development, and commercialization of therapies targeting cancer resistance mechanisms, with a portfolio of small molecule programs aimed at specific oncogenic pathways.
Leadership and Structure
The leadership team includes Jacob Chacko, MD, as CEO. The company is structured around research and development activities centered on its oncology drug programs.
Top Products and Market Share
Key Offerings
- ORIC-114 (Glucocorticoid Receptor Antagonist): A potent, selective, orally bioavailable glucocorticoid receptor (GR) antagonist in Phase 1/2 clinical development for advanced solid tumors. Competitors include companies developing other GR antagonists or therapies for similar cancer types, like Xencor.
- ORIC-533 (Potent Inhibitor of Polycomb Repressive Complex 2 (PRC2): An orally bioavailable PRC2 inhibitor currently in Phase 1/2 development for treatment of Prostate Cancer and potentially other tumors. Competitors include companies developing PRC2 inhibitors, like Constellation Pharmaceuticals (acquired by MorphoSys).
- ORIC-944 (EHMT inhibitor): An EHMT inhibitor, ORIC-944, for prostate cancer. It is anticipated to enter Phase 1/2 clinical trials in 2024. Competitors include companies developing other drugs for similar cancers, such as Johnson & Johnson.
Market Dynamics
Industry Overview
The oncology market is large and rapidly evolving, driven by advancements in personalized medicine and targeted therapies. There is a growing need for drugs that overcome resistance mechanisms in cancer.
Positioning
Oric Pharmaceuticals is positioned as a precision medicine company focused on overcoming resistance to existing cancer therapies through the development of targeted small molecule inhibitors.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Oric is focusing on niche patient populations within larger cancer types; the TAM depends on clinical success and market penetration of specific drug candidates. Figures vary based on specific indications, potentially in the billions annually for successful products.
Upturn SWOT Analysis
Strengths
- Targeted drug development approach
- Strong scientific team
- Focus on overcoming resistance mechanisms in cancer
- Proprietary small molecule inhibitors
- Experienced management team
Weaknesses
- Clinical trial execution risk
- Dependence on successful clinical trial outcomes
- Limited commercialization experience as a pre-commercial company
- High cash burn rate
- Competition from larger pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal research or acquisitions
- Positive clinical trial results leading to accelerated approval
- Advancements in diagnostic technologies for patient stratification
- Growing demand for personalized cancer therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established cancer therapies
- Patent challenges
- Economic downturn impacting funding for biotech companies
Competitors and Market Share
Key Competitors
- JNJ
- MRTX
- ARRY
Competitive Landscape
Oric is a smaller biotech company competing with larger pharmaceutical companies. Oric's strength lies in its targeted approach and focus on resistance mechanisms. It faces challenges related to clinical trial execution and competition from established therapies.
Growth Trajectory and Initiatives
Historical Growth: Oric's historical growth has been characterized by expansion of its drug pipeline and progression of clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes and potential commercialization or partnering of its drug candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for ORIC-114 and ORIC-533 and initiating pre-clinical work for ORIC-944.
Summary
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising pipeline of targeted cancer therapies. Its success hinges on the outcomes of its clinical trials and the ability to secure partnerships. The company faces risks related to clinical trial failures and competition, requiring careful financial and operational management to achieve its goals. It has potential opportunities within personalized cancer therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oric Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-04-24 | President, CEO & Director Dr. Jacob M. Chacko M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.oricpharma.com |
Full time employees 128 | Website https://www.oricpharma.com | ||
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.